Compass Therapeutics Announces Publication of Phase 2/3 COMPANION-002 Results for Tovecimig in the Journal of Clinical Oncology and Oral Presentation at ESMO 2026GlobeNewsWire · 1 day ago
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire · Oct 14, 2026
Compass Therapeutics: A Promising, But Shrinking, Window Of OpportunitySeeking Alpha · Sep 23, 2026
Compass Therapeutics Craters, FDA Pushes Survival-Trial Demand for Cancer DrugBenzinga · Sep 22, 2026
Compass Therapeutics Provides Regulatory Update on Tovecimig in Biliary Tract Cancer Following FDA FeedbackGlobeNewsWire · Sep 22, 2026
Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate UpdateGlobeNewsWire · Aug 6, 2026Compass Therapeutics, Inc. is a biopharmaceutical firm focused on developing cancer treatments, with several therapeutic candidates currently in clinical trials. The company's work involves creating antibody-based medicines designed to address a variety of human health conditions. Among its leading clinical-stage programs are CTX-009, an experimental bispecific antibody engineered to inhibit the Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, both of which are crucial for the growth of new blood vessels and tumor vascularization.
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 6, 2026 | -$0.11 | -$0.13 | Miss |
| May 5, 2026 | -$0.10 | -$0.10 | Beat |
| Mar 5, 2026 | -$0.10 | -$0.09 | Beat |
| Nov 5, 2025 | -$0.14 | -$0.08 | Beat |
| Aug 11, 2025 | -$0.13 | -$0.14 | Miss |
| May 8, 2025 | -$0.12 | -$0.12 | Beat |